Esperion Therap (ESPR) Posts Q1 Loss of 51c/Share

Esperion Therap (NASDAQ: ESPR) reported Q1 EPS of ($0.51), $0.11 better than the analyst estimate of ($0.62).

For earnings history and earnings-related data on Esperion Therap (ESPR) click here.

You May Also Be Interested In

• Evercore cuts HPE rating amid 'tougher setup'
• Perdoceo to acquire South University for up to $204M
• Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma